Surgeons say she actually is now well enough to come back home. If follow-up examinations continue to show no sign of any tumor, another steps will be to reconstruct the partially taken out pelvis and give her an artificial hip.D., Ph.D., Jean Reignier, M.D., Ph.D., Jean-Christophe Richard, M.D., Ph.D., Pascal Beuret, M.D., Arnaud Gacouin, M.D., Thierry Boulain, M.D., Emmanuelle Mercier, M.D., Michel Badet, M.D., Alain Mercat, M.D., Ph.D., Olivier Baudin, M.D., Marc Clavel, M.D., Delphine Chatellier, M.D., Samir Jaber, M.D., Ph.D.D., Jordi Mancebo, M.D., Ph.D., Michel Sirodot, M.D., Gilles Hilbert, M.D., Ph.D., Christian Bengler, M.D., Jack Richecoeur, M.D., Marc Gainnier, M.D., Ph.D.D., Gael Bourdin, M.D.D., Raphaele Girard, M.D., Loredana Baboi, Ph.D., and Louis Ayzac, M.D.The excess data will be shown in Vancouver at the 9th International Congress on Systemic Lupus Erythematosus on Friday and Saturday, June 25-26. Freimuth, M.D., Ph.D., Vice President, Clinical Research – Immunology, Rheumatology and Infectious Diseases, HGS. Significantly, belimumab didn’t significantly affect the ability of SLE individuals to maintain a defensive response to vaccines, a discovering that is in keeping with the preservation of memory B-cells. KEY BLISS-76 Results PRESENTED AT THE INTERNATIONAL CONGRESS ON SLE BLISS-76 Patient Response Rates BLISS-76 data recently presented at the 2010 Congress of the European League Against Rheumatism demonstrated that belimumab 10 mg/kg plus standard of treatment met the principal endpoint of the Phase 3 study by attaining a statistically significant improvement in patient response price as measured by the SLE Responder Index at Week 52, weighed against placebo plus standard of treatment.